Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) is 15.93% higher on its value in year-to-date trading and has touched a low of $0.42 and a high of $2.05 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ADAP stock was last observed hovering at around $0.97 in the last trading session, with the day’s loss setting it -0.05%.
Currently trading at $0.92, the stock is -16.82% and -19.62% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.76 million and changing -5.32% at the moment leaves the stock -16.53% off its SMA200. ADAP registered 20.96% gain for a year compared to 6-month loss of -39.52%. The firm has a 50-day simple moving average (SMA 50) of $1.13668 and a 200-day simple moving average (SMA200) of $1.10313.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -30.88% gain in the last 1 month and extending the period to 3 months gives it a 10.56%, and is -11.61% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.75% over the week and 6.77% over the month.
Adaptimmune Therapeutics Plc ADR (ADAP) has around 449 employees, a market worth around $235.07M and $141.56M in sales. Profit margin for the company is -51.25%. Distance from 52-week low is 118.88% and -55.16% from its 52-week high. The company has generated returns on investments over the last 12 months (-52.44%).
Adaptimmune Therapeutics Plc ADR quarterly earnings per share for the current quarter are estimated at -0.15 with sales reaching $11.1M over the same period.The EPS is expected to grow by 46.18% this year, but quarterly earnings will post 166.90% year-over-year. Quarterly sales are estimated to grow 51.70% in year-over-year returns.
95.0 institutions hold shares in Adaptimmune Therapeutics Plc ADR (ADAP), with institutional investors hold 62.08% of the company’s shares. The shares outstanding are 227.17M, and float is at 226.31M with Short Float at 3.09%. Institutions hold 61.84% of the Float.
The top institutional shareholder in the company is MATRIX CAPITAL MANAGEMENT COMPANY, LP with over 38.97 million shares valued at $38.0 million. The investor’s holdings represent 16.1135 of the ADAP Shares outstanding. As of 2024-06-30, the second largest holder is ECOR1 CAPITAL, LLC with 27.4 million shares valued at $26.72 million to account for 11.3299 of the shares outstanding. The other top investors are NEA MANAGEMENT COMPANY, LLC which holds 17.08 million shares representing 7.0614 and valued at over $16.65 million, while BAILLIE GIFFORD & CO holds 6.2633 of the shares totaling 15.15 million with a market value of $14.77 million.
Adaptimmune Therapeutics Plc ADR (ADAP) Insider Activity
The most recent transaction is an insider sale by Piccina Cintia, the company’s Chief Commercial Officer. SEC filings show that Piccina Cintia sold 24,531 shares of the company’s common stock on Jun 18 ’24 at a price of $0.93 per share for a total of $22814.0. Following the sale, the insider now owns 38293.0 shares.
Adaptimmune Therapeutics Plc ADR disclosed in a document filed with the SEC on Jan 17 ’24 that Rawcliffe Adrian (Chief Executive Officer) sold a total of 30,080 shares of the company’s common stock. The trade occurred on Jan 17 ’24 and was made at $0.67 per share for $20244.0. Following the transaction, the insider now directly holds 44848.0 shares of the ADAP stock.
Still, SEC filings show that on Jan 16 ’24, Rawcliffe Adrian (Chief Executive Officer) disposed off 9,304 shares at an average price of $0.79 for $7350.0. The insider now directly holds 14,104 shares of Adaptimmune Therapeutics Plc ADR (ADAP).
